滤泡性淋巴瘤中克隆性IgH/Bcl2 MBR重排的可靠检测：方法与临床意义
Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: methodology and clinical significance.
作者信息
Iqbal Sameena, Jenner Michael J R, Summers Karin E, Davies Andrew J, Matthews Janet, Norton Andrew J, Calaminici Maria, Rohatiner Ama Z, Fitzgibbon Jude, Lister T Andrew, Goff Lindsey K
机构信息
Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, Charterhouse Square, West Smithfield, London EC1M 6BQ, UK.
出版信息
Br J Haematol. 2004 Feb;124(3):325-8. doi: 10.1046/j.1365-2141.2003.04796.x.
The prognostic significance of IgH/Bcl2 rearrangement in follicular lymphoma (FL) remains contentious; polymerase chain reaction (PCR) methodology and tissue source variability may account for some inconsistencies. As IgH/Bcl2 major breakpoint region (MBR) sequences may be found in normal blood, an MBR+ result by conventional PCR in blood/bone marrow may not indicate FL. To establish tumour MBR status, 190 lymphoid tissue samples with histologically evident FL (and therefore >1% tumour cells) were examined by real-time quantifiable PCR; 50% (95/190) had clonal MBR IgH/Bcl2 (MBR was considered clonal when >1%). Overall survival (median = 11.5 years) of MBR+ and MBR- patients was not significantly different.
免疫球蛋白重链（IgH）/Bcl2重排在滤泡性淋巴瘤（FL）中的预后意义仍存在争议；聚合酶链反应（PCR）方法和组织来源的变异性可能是造成一些不一致结果的原因。由于在正常血液中可能会发现IgH/Bcl2主要断裂点区域（MBR）序列，因此血液/骨髓中通过传统PCR检测出的MBR+结果可能并不意味着患有FL。为确定肿瘤MBR状态，采用实时定量PCR对190份组织学确诊为FL（因此肿瘤细胞>1%）的淋巴组织样本进行检测；50%（95/190）的样本具有克隆性MBR IgH/Bcl2（当>1%时MBR被认为是克隆性的）。MBR+和MBR-患者的总生存期（中位数=11.5年）无显著差异。
Zotero 插件